



Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study

Ennio Giulio Favalli^{1,2*†}, Andrea Gobbin^{3†}, Mauro Bombaci^{3†}, Gabriella Maioli^{1,2}, Martina Biggoggero¹, Elisa Pesce³, Andrea Favalli³, Martina Martinovic³, Tanya Fabbris³, Edoardo Marchisio⁴, Alessandra Bandera^{5,6,7}, Andrea Gori^{5,6,7}, Sergio Abrignani^{3†}, Renata Grifantini^{3†} and Roberto Caporali^{1,2†}

OPEN ACCESS

Approved by:
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

***Correspondence:**
Ennio Giulio Favalli
enniofavalli@me.com

[†]These authors have contributed
equally to this work

Specialty section:
This article was submitted to
Rheumatology,
a section of the journal
Frontiers in Medicine

Received: 19 April 2022
Accepted: 20 April 2022
Published: 04 May 2022

Citation:
Favalli EG, Gobbin A, Bombaci M,
Maioli G, Biggoggero M, Pesce E,
Favalli A, Martinovic M, Fabbris T,
Marchisio E, Bandera A, Gori A,
Abrignani S, Grifantini R and
Caporali R (2022) Corrigendum: The
Impact of Anti-rheumatic Drugs on the
Seroprevalence of Anti-SARS-CoV-2
Antibodies in a Cohort of Patients
With Inflammatory Arthritis: The
MAINSTREAM Study.
Front. Med. 9:923790.
doi: 10.3389/fmed.2022.923790

¹ Division of Clinical Rheumatology, ASST Gaetano Pini-CTO Institute, Milan, Italy, ² Department of Clinical Sciences and Community Health, Research Center for Adult and Pediatric Rheumatic Diseases, Università degli Studi di Milano, Milan, Italy, ³ Istituto Nazionale Genetica Molecolare, Padiglione Romeo ed Enrica Invernizzi, Milan, Italy, ⁴ Dia.Pro, Diagnostic Bioprobes Srl, Milan, Italy, ⁵ Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ⁶ Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy, ⁷ Centre for Multidisciplinary Research in Health Science (MACH), Università degli Studi di Milano, Milan, Italy

Keywords: seroprevalence, SARS-CoV-2, humoral response, rheumatic musculoskeletal diseases, disease-modifying anti-rheumatic drugs, risk of infection, COVID-19

A Corrigendum on

The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
by Favalli, E. G., Gobbin, A., Bombaci, M., Maioli, G., Biggoggero, M., Pesce, E., Favalli, A., Martinovic, M., Fabbris, T., Marchisio, E., Bandiera, A., Gori, A., Abrignani, S., Grifantini, R., and Caporali, R. (2022). *Front. Med.* 9:850858. doi: 10.3389/fmed.2022.850858

In the original article, an author name was incorrectly spelled as “Alessandra Bandiera.” The correct spelling is “Alessandra Bandera.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Favalli, Gobbin, Bombaci, Maioli, Biggoggero, Pesce, Favalli, Martinovic, Fabbris, Marchisio, Bandera, Gori, Abrignani, Grifantini and Caporali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.